中国癌症杂志2024,Vol.34Issue(1) :90-96.DOI:10.19401/j.cnki.1007-3639.2024.01.006

卵巢黏液性癌的诊治进展

Progress in diagnosis and treatment of mucinous ovarian cancer

李桐 杨慧娟
中国癌症杂志2024,Vol.34Issue(1) :90-96.DOI:10.19401/j.cnki.1007-3639.2024.01.006

卵巢黏液性癌的诊治进展

Progress in diagnosis and treatment of mucinous ovarian cancer

李桐 1杨慧娟2
扫码查看

作者信息

  • 1. 复旦大学附属肿瘤医院胸外科,复旦大学遗传工程国家重点实验室,复旦大学胸部肿瘤研究所,复旦大学上海医学院肿瘤学系,上海 200032
  • 2. 复旦大学附属肿瘤医院妇瘤科,复旦大学上海医学院肿瘤学系,上海 200032
  • 折叠

摘要

卵巢黏液性癌(mucinous ovarian cancer,MOC)是卵巢上皮性癌的一种罕见病理学类型,临床上治疗多参考卵巢浆液性癌(serous ovarian cancer,SOC)的相关指南,但由于MOC的临床病理学特征和分子生物学特征与SOC显著不同,因此诊断和治疗均需仔细鉴别.手术联合辅助化疗为目前治疗MOC的标准方案,但由于其患病率低,临床试验难以开展,循证医学证据缺乏,术中阑尾切除指征、术后辅助化疗方案的选择等均缺乏共识.此外,还需进一步转化靶向治疗和免疫治疗的临床前研究,以利于MOC的精准诊断及个体化治疗.

Abstract

Mucinous ovarian cancer(MOC)is a rare pathological type different from epithelial ovarian cancer,and the clinical treatment should refer to serous ovarian cancer(SOC)guidelines.However,since the clinicopathological features of MOC are significantly different from SOC,careful differentiation is needed in diagnosis and treatment.Surgery combined with adjuvant chemotherapy is the standard treatment for MOC.However,due to the low prevalence rate,it is difficult to carry out clinical trials,hence lacking evidence-based medicine and consensus on the indications of intraoperative appendectomy and the choice of postoperative adjuvant chemotherapy.In addition,further translational preclinical studies of targeted therapy and immunotherapy are needed to facilitate the diagnosis and individualized treatment of MOC.

关键词

卵巢癌/卵巢黏液性癌/诊治进展

Key words

Ovarian cancer/Mucinous ovarian cancer/Progress in diagnosis and treatment

引用本文复制引用

出版年

2024
中国癌症杂志
复旦大学附属肿瘤医院

中国癌症杂志

CSTPCD北大核心
影响因子:2.015
ISSN:1007-3639
参考文献量1
段落导航相关论文